| Literature DB >> 33462406 |
Charlotte Pandiani1,2, Thomas Strub1,2, Nicolas Nottet1,2, Yann Cheli1,2, Giovanni Gambi3, Karine Bille1,2, Chrystel Husser1,2, Mélanie Dalmasso1,2, Guillaume Béranger1,2, Sandra Lassalle1,4, Virginie Magnone1,5, Florence Pédeutour1,6, Marie Irondelle1,7, Célia Maschi1,8, Sacha Nahon-Estève1,8, Arnaud Martel1,8, Jean-Pierre Caujolle1,8, Paul Hofman1,4, Kévin LeBrigand1,5, Irwin Davidson3, Stéphanie Baillif1,8, Pascal Barbry1,5, Robert Ballotti1,2, Corine Bertolotto9,10.
Abstract
Intratumor heterogeneity has been recognized in numerous cancers as a major source of metastatic dissemination. In uveal melanomas, the existence and identity of specific subpopulations, their biological function and their contribution to metastasis remain unknown. Here, in multiscale analyses using single-cell RNA sequencing of six different primary uveal melanomas, we uncover an intratumoral heterogeneity at the genomic and transcriptomic level. We identify distinct transcriptional cell states and diverse tumor-associated populations in a subset of the samples. We also decipher a gene regulatory network underlying an invasive and poor prognosis state driven in part by the transcription factor HES6. HES6 heterogenous expression has been validated by RNAscope assays within primary human uveal melanomas, which further unveils the existence of these cells conveying a dismal prognosis in tumors diagnosed with a favorable outcome using bulk analyses. Depletion of HES6 impairs proliferation, migration and metastatic dissemination in vitro and in vivo using the chick chorioallantoic membrane assay, demonstrating the essential role of HES6 in uveal melanomas. Thus, single-cell analysis offers an unprecedented view of primary uveal melanoma heterogeneity, identifies bona fide biomarkers for metastatic cells in the primary tumor, and reveals targetable modules driving growth and metastasis formation. Significantly, our findings demonstrate that HES6 is a valid target to stop uveal melanoma progression.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33462406 PMCID: PMC8185008 DOI: 10.1038/s41418-020-00730-7
Source DB: PubMed Journal: Cell Death Differ ISSN: 1350-9047 Impact factor: 12.067